S Wolowacz1, I Pearson1, P Shannon2, B Chubb3, J Gundgaard4, M Davies5, A Briggs6. 1. Health Economics, RTI Health Solutions, Manchester. 2. Patient-Reported Outcomes, RTI Health Solutions, Manchester. 3. European Health Economics & Outcomes Research, Novo Nordisk Ltd, Gatwick, UK. 4. Health Economics and HTA, Novo Nordisk A/S, Bagsvaerd, Denmark. 5. Diabetes Research Centre, University of Leicester, Leicester. 6. Institute for Health and Wellbeing, University of Glasgow, Glasgow, UK.
Abstract
AIMS: To develop a health economic model to evaluate the cost-effectiveness of new interventions for Type 1 diabetes mellitus by their effects on long-term complications (measured through mean HbA1c ) while capturing the impact of treatment on hypoglycaemic events. METHODS: Through a systematic review, we identified complications associated with Type 1 diabetes mellitus and data describing the long-term incidence of these complications. An individual patient simulation model was developed and included the following complications: cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, proliferative retinopathy, ketoacidosis, cataract, hypoglycemia and adverse birth outcomes. Risk equations were developed from published cumulative incidence data and hazard ratios for the effect of HbA1c , age and duration of diabetes. We validated the model by comparing model predictions with observed outcomes from studies used to build the model (internal validation) and from other published data (external validation). We performed illustrative analyses for typical patient cohorts and a hypothetical intervention. RESULTS: Model predictions were within 2% of expected values in the internal validation and within 8% of observed values in the external validation (percentages represent absolute differences in the cumulative incidence). CONCLUSIONS: The model utilized high-quality, recent data specific to people with Type 1 diabetes mellitus. In the model validation, results deviated less than 8% from expected values.
AIMS: To develop a health economic model to evaluate the cost-effectiveness of new interventions for Type 1 diabetes mellitus by their effects on long-term complications (measured through mean HbA1c ) while capturing the impact of treatment on hypoglycaemic events. METHODS: Through a systematic review, we identified complications associated with Type 1 diabetes mellitus and data describing the long-term incidence of these complications. An individual patient simulation model was developed and included the following complications: cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, proliferative retinopathy, ketoacidosis, cataract, hypoglycemia and adverse birth outcomes. Risk equations were developed from published cumulative incidence data and hazard ratios for the effect of HbA1c , age and duration of diabetes. We validated the model by comparing model predictions with observed outcomes from studies used to build the model (internal validation) and from other published data (external validation). We performed illustrative analyses for typical patient cohorts and a hypothetical intervention. RESULTS: Model predictions were within 2% of expected values in the internal validation and within 8% of observed values in the external validation (percentages represent absolute differences in the cumulative incidence). CONCLUSIONS: The model utilized high-quality, recent data specific to people with Type 1 diabetes mellitus. In the model validation, results deviated less than 8% from expected values.
Authors: Wen Wan; M Reza Skandari; Alexa Minc; Aviva G Nathan; Parmida Zarei; Aaron N Winn; Michael O'Grady; Elbert S Huang Journal: Med Decis Making Date: 2018-11 Impact factor: 2.583
Authors: David Russell-Jones; Simon R Heller; Sarah Buchs; Anna Sandberg; William J Valentine; Barnaby Hunt Journal: Diabetes Obes Metab Date: 2017-07-25 Impact factor: 6.577
Authors: An Tran-Duy; Josh Knight; Andrew J Palmer; Dennis Petrie; Tom W C Lung; William H Herman; Björn Eliasson; Ann-Marie Svensson; Philip M Clarke Journal: Diabetes Care Date: 2020-06-12 Impact factor: 19.112